A Phase 2 interventional study of vilobelimab in Pyoderma Gangrenosum, sponsored by InflaRx GmbH. Completed at 10 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-14.
Sponsored by InflaRx GmbH · Phase 2, Interventional, and Treatment
The purpose of this study is to determine whether vilobelimab (development name: IFX-1) is safe and effective in the treatment of pyoderma gangrenosum.
Neutrophilic dermatoses are a spectrum of inflammatory disorders characterized by skin lesions resulting from a neutrophil-rich inflammatory infiltrate in the absence of infection. Pyoderma gangrenosum is associated with a neutrophilic leukocytosis, which is likely to be triggered by C5a. This study is set up based on the hypothesis that vilobelimab might be able to block C5a induced pro-inflammatory effects such as neutrophil activation and cytokine generation, potentially contributing to the local skin inflammation and tissue damage.
36 studies on the registry are indexed under Pyoderma Gangrenosum; 7 are open to participants now.
This study's enrollment of 19 is above the median of 10 across 26 interventional studies indexed under Pyoderma Gangrenosum.
Browse Pyoderma Gangrenosum studies →InflaRx GmbH is the lead sponsor of 12 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In addition, the subject must fulfill at least 3 of the following 6 criteria at screening:
History of
Clinical examination (or photographic evidence) of
Subject has a minimum of 1 evaluable ulcer (≥2 cm2) on the lower extremity at screening
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose finding with a total of 15 doses of vilobelimab. Vilobelimab: IV infusions of vilobelimab diluted in sodium chloride. All patients received vilobelimab 800 mg three times during the first week (Days 1, 4, and 8). Starting at Day 15: Group 1 (N=6) continued to receive vilobelimab 800 mg every 2 weeks (Q2W), with option to increase dose from Day 57 to 1600 mg every Q2W.
Drug: vilobelimab
Dose finding with a total of 15 doses of vilobelimab. Vilobelimab: IV infusions of vilobelimab diluted in sodium chloride. All patients received vilobelimab 800 mg three times during the first week (Days 1, 4, and 8). Starting at Day 15: Group 2 (N=6) received vilobelimab 1600 mg every 2 weeks (Q2W), with option to increase dose from Day 57 to 2400 mg every Q2W.
Drug: vilobelimab
Dose finding with a total of 15 doses of vilobelimab. Vilobelimab: IV infusions of vilobelimab diluted in sodium chloride. All patients received vilobelimab 800 mg three times during the first week (Days 1, 4, and 8). Starting at Day 15: Group 3 (N=7) received vilobelimab 2400 mg every Q2W.
Drug: vilobelimab
IV infusions of vilobelimab diluted in sodium chloride.
Also known as: IFX-1, CaCP29
Treatment-emergent Adverse Events (TEAEs), Related TEAEs, Serious TEAEs, and Adverse Events of Special Interest (AESIs)
Number of patients with treatment-emergent adverse events (TEAEs), related TEAEs, serious TEAEs, and adverse events of special interest (AESIs) TEAEs are defined as adverse events that start at or after the first administration of study drug. Related TEAEs are defined as all TEAEs considered by the investigator to have at least a 'possible' relationship with the study drug. AESIs are defined as infusion-related reactions, including acute and delayed hypersensitivity and anaphylactic reactions during or after infusion; Meningitis; Meningococcal septicaemia; Invasive infection. As adverse events will be reported in details in the safety section, no separate reporting on System Organ Class (SOC) or Preferred Term (PT) level etc. is done here.
Time frame: From treatment start until end of study (including observational visits), an average of 249 days
Number of Patients With Physician's Global Assessment (PGA) Score ≤3 (Investigator Assessment)
Efficacy endpoint: Proportion of patients with a clinical response, defined as Physician's Global Assessment (PGA) score ≤3 of target ulcer at Visit V4, V6, V10 and V16 (End of Treatment \[EOT\]) (SAF). PGA values: 0 = Completely clear, 1 = Almost clear, 2 =Marked improvement, 3 = Moderate improvement, 4 = Slight improvement, 5 = No change from baseline, 6 = Worse
Time frame: From treatment start until V16 (Day 189)
Time to Complete Closure of Pyoderma Gangrenosum Target Ulcer (Investigator Assessment) [Days]
Efficacy endpoint: Kaplan-Meier analysis of time to first clinical remission (complete closure of target ulcer) defined as PGA score of ≤ 1, PGA values: 0 = Completely clear, 1 = Almost clear, 2 =Marked improvement, 3 = Moderate improvement, 4 = Slight improvement, 5 = No change from baseline, 6 = Worse
Time frame: From treatment start until end of study (including observational visits), an average of 249 days
Percentage Change in Wound Healing (Wound Area) by Photographic Assessment
Efficacy endpoint: Percentage change in wound area \[percent change\] of target ulcer by photographic assessment between Visits V1 and V4, between Visits V1 and V6, between Visits V1 and V16, between Visits V6 and V10, between Visits V10 and V16.
Time frame: From treatment start until V16 (Day 189)
Percentage Change in Wound Healing (Wound Volume) by Photographic Assessment
Efficacy endpoint: Percentage change in wound volume \[percent change\] of target ulcer by photographic assessment between Visits V1 and V4, between Visits V1 and V6, between Visits V1 and V16, between Visits V6 and V10, between Visits V10 and V16.
Time frame: From treatment start until V16 (Day 189)
Rate of Change Per Day in Area of Target Ulcer by Photographic Assessment From V1 to V16
Efficacy endpoint: Rate of change per day in area of target ulcer \[mm²/day\] between Visits V1 and V16 (photographic assessment)
Time frame: From treatment start until V16 (Day 189)
Number of Patients With ≥ 50% Decrease in Area of Target Ulcer by Photographic Assessment at V16
Efficacy endpoint: Number of patients with a decrease in area of target ulcer of ≥ 50% by photographic assessment at Visit V16 (EOT) compared to Baseline
Time frame: From treatment start until V16 (Day 189)
Number of Patients With 100% Decrease in Area of Target Ulcer at V16
Efficacy endpoint: Number of patients with a decrease in area of target ulcer of 100% at Visit V16 (EOT) compared to Baseline (remission) (photographic assessment)
Time frame: From treatment start until V16 (Day 189)
Degree of Erythema of the Target Ulcer at V4, V6, V10 and V16
Efficacy endpoint: Degree of erythema of the target ulcer at Visit V4, V6, V10 and V16 (EOT) (investigator assessment)
Time frame: From treatment start until V16 (Day 189)
Border Elevation of the Target Ulcer at Visits V4, V6, V10 and V16
Efficacy endpoint: Border elevation of the target ulcer at visits V4, V6, V10 and V16 (EOT) (investigator assessment)
Time frame: From treatment start until V16 (Day 189)
Percentage Change in Pain by Numeric Rating Scale (NRS) at Visits V4, V6, V10 and V16
Efficacy endpoint: Percentage change from Baseline in pain assessed by Numeric Rating Scale (NRS) \[percent change\] at visits V4, V6, V10 and V16 (EOT) Mean (SD) The NRS is an 11-point scale (from 0 represent no pain to 10 representing the worst pain the subject can imagine).
Time frame: From treatment start until V16 (Day 189)
Percentage Change in Life Quality by DLQI at Visits V4, V6, V10, and V16
Efficacy endpoint: Percentage change from Baseline in Dermatology Life Quality Index (DLQI) \[percent change\] at visits V4, V6, V10, and V16 (EOT) The DLQI comprises 10 questions with single scores 0 (No effect on patient's life) to 3 (large effect on patient's life). The DLQI total score is calculated by summing up the score of each question resulting in a minimum of 0 (best) and a maximum of 30 (worst).
Time frame: From treatment start until V16 (Day 189)
| Milestone | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| Started | 6 | 6 | 7 |
| Completed until day 99 (evaluable) | 6 | 4 | 7 |
| Completed | 1 | 3 | 6 |
| Not completed | 5 | 3 | 1 |
Number of patients with treatment-emergent adverse events (TEAEs), related TEAEs, serious TEAEs, and adverse events of special interest (AESIs) TEAEs are defined as adverse events that start at or after the first administration of study drug. Related TEAEs are defined as all TEAEs considered by the investigator to have at least a 'possible' relationship with the study drug. AESIs are defined as infusion-related reactions, including acute and delayed hypersensitivity and anaphylactic reactions during or after infusion; Meningitis; Meningococcal septicaemia; Invasive infection. As adverse events will be reported in details in the safety section, no separate reporting on System Organ Class (SOC) or Preferred Term (PT) level etc. is done here.
| Participants | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| Treatment-emergent adverse events (TEAEs) | 6 | 4 | 5 |
| Related TEAEs | 0 | 2 | 2 |
| Serious TEAEs | 1 | 1 | 2 |
| Adverse events of special interest (AESIs) as identified by investigator | 0 | 1 | 1 |
| Adverse events of special interest (AESIs) as identified by sponsor | 2 | 1 | 2 |
Efficacy endpoint: Proportion of patients with a clinical response, defined as Physician's Global Assessment (PGA) score ≤3 of target ulcer at Visit V4, V6, V10 and V16 (End of Treatment \[EOT\]) (SAF). PGA values: 0 = Completely clear, 1 = Almost clear, 2 =Marked improvement, 3 = Moderate improvement, 4 = Slight improvement, 5 = No change from baseline, 6 = Worse
| Participants | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| V4 | 2 | 0 | 0 |
| V6 | 1 | 1 | 3 |
| V10 | 3 | 1 | 5 |
| V16 | 0 | 1 | 5 |
Efficacy endpoint: Kaplan-Meier analysis of time to first clinical remission (complete closure of target ulcer) defined as PGA score of ≤ 1, PGA values: 0 = Completely clear, 1 = Almost clear, 2 =Marked improvement, 3 = Moderate improvement, 4 = Slight improvement, 5 = No change from baseline, 6 = Worse
| days | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| Time to Complete Closure of Pyoderma Gangrenosum Target Ulcer (Investigator Assessment) [Days] | NA (62 to NA) | NA (NA to NA) | 126 (77 to 197) |
Efficacy endpoint: Percentage change in wound area \[percent change\] of target ulcer by photographic assessment between Visits V1 and V4, between Visits V1 and V6, between Visits V1 and V16, between Visits V6 and V10, between Visits V10 and V16.
| percent change | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| V1-V4 | -13.612 ± 41.7862 | 16.099 ± 15.0992 | -12.620 ± 31.9371 |
| V1-V6 | -4.130 ± 74.1725 | -8.413 ± 47.5261 | -34.153 ± 53.3455 |
| V1-V16 | 234.068 | -57.538 ± 60.0506 | -90.918 ± 16.2280 |
| V6-V10 | -22.803 ± 52.8937 | -16.198 ± 58.8229 | -63.059 ± 50.1507 |
| V10-V16 | 61.451 | 8.644 ± 5.2038 | -51.141 ± 69.4133 |
Efficacy endpoint: Percentage change in wound volume \[percent change\] of target ulcer by photographic assessment between Visits V1 and V4, between Visits V1 and V6, between Visits V1 and V16, between Visits V6 and V10, between Visits V10 and V16.
| percent change | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| V1-V4 | -19.733 ± 53.4282 | 74.918 | -36.328 ± 32.3445 |
| V1-V6 | -17.300 ± 90.9283 | — | -58.959 ± 46.7969 |
| V1-V16 | 786.937 | — | -92.639 ± 15.6580 |
| V6-V10 | -38.033 ± 82.8031 | -100.000 | -82.525 ± 30.2680 |
| V10-V16 | 150.857 | — | 4.167 ± 177.7658 |
Efficacy endpoint: Rate of change per day in area of target ulcer \[mm²/day\] between Visits V1 and V16 (photographic assessment)
| mm²/day | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| Rate of Change Per Day in Area of Target Ulcer by Photographic Assessment From V1 to V16 | 15.14 | -12.04 ± 9.638 | -9.58 ± 10.751 |
Efficacy endpoint: Number of patients with a decrease in area of target ulcer of ≥ 50% by photographic assessment at Visit V16 (EOT) compared to Baseline
| Participants | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| Number of Patients With ≥ 50% Decrease in Area of Target Ulcer by Photographic Assessment at V16 | 0 | 1 | 6 |
Efficacy endpoint: Number of patients with a decrease in area of target ulcer of 100% at Visit V16 (EOT) compared to Baseline (remission) (photographic assessment)
| Participants | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| Number of Patients With 100% Decrease in Area of Target Ulcer at V16 | 0 | 1 | 2 |
Efficacy endpoint: Degree of erythema of the target ulcer at Visit V4, V6, V10 and V16 (EOT) (investigator assessment)
| Participants | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| V4 — None (0) | 0 | 0 | 0 |
| V4 — Slight (1) | 0 | 0 | 0 |
| V4 — Moderate (2) | 2 | 2 | 1 |
| V4 — Severe (3) | 3 | 3 | 4 |
| V4 — Very severe (4) | 1 | 1 | 2 |
| V6 — None (0) | 1 | 0 | 0 |
| V6 — Slight (1) | 0 | 0 | 1 |
| V6 — Moderate (2) | 2 | 2 | 2 |
| V6 — Severe (3) | 2 | 2 | 3 |
| V6 — Very severe (4) | 1 | 0 | 1 |
| V10 — None (0) | 1 | 0 | 0 |
| V10 — Slight (1) | 0 | 1 | 3 |
| V10 — Moderate (2) | 3 | 1 | 1 |
| V10 — Severe (3) | 2 | 2 | 2 |
| V10 — Very severe (4) | 0 | 0 | 0 |
| V16 — None (0) | 0 | 1 | 0 |
| V16 — Slight (1) | 0 | 1 | 5 |
| V16 — Moderate (2) | 0 | 0 | 1 |
| V16 — Severe (3) | 1 | 1 | 0 |
| V16 — Very severe (4) | 0 | 0 | 0 |
Efficacy endpoint: Border elevation of the target ulcer at visits V4, V6, V10 and V16 (EOT) (investigator assessment)
| Participants | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| V4 — None (0) | 0 | 0 | 0 |
| V4 — Slight (1) | 2 | 0 | 0 |
| V4 — Moderate (2) | 1 | 5 | 4 |
| V4 — Severe (3) | 3 | 0 | 3 |
| V4 — Very severe (4) | 0 | 1 | 0 |
| V6 — None (0) | 2 | 0 | 1 |
| V6 — Slight (1) | 1 | 0 | 1 |
| V6 — Moderate (2) | 2 | 3 | 4 |
| V6 — Severe (3) | 1 | 1 | 1 |
| V6 — Very severe (4) | 0 | 0 | 0 |
| V10 — None (0) | 1 | 0 | 0 |
| V10 — Slight (1) | 2 | 1 | 6 |
| V10 — Moderate (2) | 3 | 3 | 0 |
| V10 — Severe (3) | 0 | 0 | 0 |
| V10 — Very severe (4) | 0 | 0 | 0 |
| V16 — None (0) | 0 | 1 | 1 |
| V16 — Slight (1) | 0 | 1 | 4 |
| V16 — Moderate (2) | 1 | 1 | 1 |
| V16 — Severe (3) | 0 | 0 | 0 |
| V16 — Very severe (4) | 0 | 0 | 0 |
Efficacy endpoint: Percentage change from Baseline in pain assessed by Numeric Rating Scale (NRS) \[percent change\] at visits V4, V6, V10 and V16 (EOT) Mean (SD) The NRS is an 11-point scale (from 0 represent no pain to 10 representing the worst pain the subject can imagine).
| percent change | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| V1-V4 | -41.6 ± 31.29 | 10.6 ± 19.88 | -41.4 ± 33.77 |
| V1-V6 | -43.3 ± 16.43 | 1.7 ± 22.19 | -45.0 ± 45.23 |
| V1-V10 | -64.3 ± 32.55 | 32.5 ± 89.87 | -72.2 ± 32.07 |
| V1-V16 | -22.2 | 5.6 ± 141.75 | -51.6 ± 33.89 |
Efficacy endpoint: Percentage change from Baseline in Dermatology Life Quality Index (DLQI) \[percent change\] at visits V4, V6, V10, and V16 (EOT) The DLQI comprises 10 questions with single scores 0 (No effect on patient's life) to 3 (large effect on patient's life). The DLQI total score is calculated by summing up the score of each question resulting in a minimum of 0 (best) and a maximum of 30 (worst).
| percent change | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| V1-V4 | -29.9 ± 22.75 | -3.8 ± 51.05 | -33.1 ± 28.61 |
| V1-V6 | -31.4 ± 20.29 | -33.2 ± 29.68 | -24.7 ± 34.30 |
| V1-V10 | -50.0 ± 28.01 | -33.9 ± 31.26 | -43.1 ± 28.17 |
| V1-V16 | 4.5 | -2 ± 56.07 | -50.8 ± 45.10 |
Collected over From treatment start until end of study (including observational visits), an average of 249 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vilobelimab 800 mg Q2W | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Vilobelimab 1600 mg Q2W | 0/6 (0%) | 1/6 (16.7%) | 3/6 (50%) |
| Vilobelimab 2400 mg Q2W | 0/7 (0%) | 2/7 (28.6%) | 5/7 (71.4%) |
| Event | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| EndocarditisInfections and infestations | 1/6 | 0/6 | 0/7 |
| Intervertebral discitisInfections and infestations | 1/6 | 0/6 | 0/7 |
| PneumoniaInfections and infestations | 1/6 | 0/6 | 0/7 |
| SepsisInfections and infestations | 1/6 | 0/6 | 0/7 |
| RashSkin and subcutaneous tissue disorders | 0/6 | 1/6 | 0/7 |
| ErysipelasInfections and infestations | 0/6 | 0/6 | 1/7 |
| Superinfection bacterialInfections and infestations | 0/6 | 0/6 | 1/7 |
| Pyoderma gangrenosumSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 1/7 |
| Event | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W |
|---|---|---|---|
| Wound infectionInfections and infestations | 2/6 | 1/6 | 0/7 |
| Wound infection pseudomonasInfections and infestations | 2/6 | 0/6 | 0/7 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 2/6 | 0/6 | 0/7 |
| Traumatic haematomaInjury, poisoning and procedural complications | 2/6 | 0/6 | 0/7 |
| Pyoderma gangrenosumSkin and subcutaneous tissue disorders | 0/6 | 0/6 | 2/7 |
| CellulitisInfections and infestations | 1/6 | 0/6 | 0/7 |
| GingivitisInfections and infestations | 1/6 | 0/6 | 0/7 |
| ImpetigoInfections and infestations | 1/6 | 0/6 | 0/7 |
| NasopharyngitisInfections and infestations | 1/6 | 0/6 | 0/7 |
| Urinary tract infectionInfections and infestations | 1/6 | 0/6 | 0/7 |
| Age, Continuous(years) | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W | Total |
|---|---|---|---|---|
| Mean | 59.5 ± 11.41 | 60.5 ± 12.36 | 43.0 ± 15.00 | 53.7 ± 14.99 |
| Sex: Female, Male(Participants) | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W | Total |
|---|---|---|---|---|
| Female | 4 | 3 | 3 | 10 |
| Male | 2 | 3 | 4 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 6 | 6 | 6 | 18 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 2 |
| White | 6 | 4 | 7 | 17 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Baseline Disease Characteristic: Duration of pyoderma gangrenosum(years) | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W | Total |
|---|---|---|---|---|
| Mean | 1.7 ± 1.86 | 5.7 ± 9.54 | 3.4 ± 6.05 | 3.6 ± 6.41 |
| Baseline Disease Characteristic: Wound area at baseline(area [mm²]) | Vilobelimab 800 mg Q2W | Vilobelimab 1600 mg Q2W | Vilobelimab 2400 mg Q2W | Total |
|---|---|---|---|---|
| Mean | 1692.374 ± 1391.4307 | 7898.952 ± 5844.5941 | 1827.553 ± 1901.2830 | 3573.500 ± 4320.3723 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vilobelimab
InflaRx GmbH